Regeneron Pharmaceuticals, a leading U.S. biotechnology company, has secured a deal to acquire the assets of the bankrupt genetic testing firm 23andMe for $256 million. The acquisition is part of a court-supervised sale, marking a significant move for Regeneron as it aims to enhance its genetics-guided drug development. With this purchase, Regeneron promises to maintain consumer genetics services and prioritize the privacy of over 40 million customer DNA records. This acquisition underscores the transition of 23andMe from a pioneering DNA testing company to being absorbed by a pharmaceutical giant, as it seeks to leverage its genetic information in advancing health and wellness initiatives.